Ondine Biomedical Appoints Peel Hunt as Broker and Adviser

The latest announcement is out from Ondine Biomedical, Inc. ( (GB:OBI) ).

Ondine Biomedical Inc. has appointed Peel Hunt LLP as its broker and joint financial adviser to support its global business growth. Peel Hunt’s expertise in the healthcare sector and strong investor network are expected to enhance Ondine’s shareholder base and investor support, potentially impacting its market position positively.

The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, to prevent and treat infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products in development and its nasal photodisinfection system, Steriwave®, is approved in several countries and undergoing clinical trials in the US.

Average Trading Volume: 172,603

Technical Sentiment Signal: Buy

Current Market Cap: £63.16M

See more insights into OBI stock on TipRanks’ Stock Analysis page.